Several groups of PARP inhibitors (including phenanthridine derivatives) were designed to protect cells under stress conditions from cell death induced by a massive activation of PARP-1 (for example, stroke, inflammation; [10,12]), or to cause cell death in malignant cells by preventing polyADP-ribosylation-dependent DNA repair [9,11]. This evidence concerns the gene PARP1 and stroke disorder.